We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 41% below its sector, cheaper than its peers on earnings.
Ilex Medical Ltd. engages in medical diagnostics field. It operates through the following segments: Medical Laboratory Equipment and Diagnostics Materials, Medical Equipment, and Inhalation Devices. The Medical Laboratory Equipment and Diagnostics Materials segment deals with the marketing, distribution, and sale of laboratory medical equipment and diagnostics products, diagnostics systems, kits, and consumables for the examination of medical laboratories in hospitals. The Medical Equipment segment handles importation, marketing, and distribution of medical equipment and devices in Israel. The Inhalation Devices segment includes development, manufacture, and marketing of mobile inhalation devices. The company was founded by Moshe Ben Shaul in 1977 and is headquartered in Petach Tikva, Israel.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save ILX.TA and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
